← Browse by Condition
Medical Condition

hormone receptor positive tumor

Total Trials
2
Recruiting Now
2
Trial Phases
Phase 2

ClinicalMetric tracks all active clinical trials for hormone receptor positive tumor sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — hormone receptor positive tumor Clinical Trials

How many clinical trials are currently recruiting for hormone receptor positive tumor?
ClinicalMetric currently tracks 2 actively recruiting clinical trials for hormone receptor positive tumor, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 2. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for hormone receptor positive tumor?
hormone receptor positive tumor research spans Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a hormone receptor positive tumor clinical trial?
Eligibility criteria for hormone receptor positive tumor trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
1
Top Sponsors
Institute of Oncology Ljubljana 1 trial
Fudan University 1 trial

Recruiting Clinical Trials

NCT06650423
Recruiting
Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer
Enrollment
319 pts
Location
Slovenia
Sponsor
Institute of Oncology Ljubljan...
View Trial →
NCT05582499 Phase 2
Recruiting
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Enrollment
716 pts
Location
China
Sponsor
Fudan University
View Trial →

Related Conditions

her2 negative breast cancer (2) early breast cancer (1) breast neoplasm (1) breast cancer (1) breast tumors (1) triple negative breast cancer tnbc (1) her2 positive breast cancer (1) hormone receptor negative tumor (1) early stage breast cancer (1) locally advanced breast cancer (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology